Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2004-01-23
2009-08-18
Huynh, Phuong (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S252330, C435S320100, C435S326000, C435S335000, C530S387100, C530S387300, C530S388100, C530S388230, C536S023530
Reexamination Certificate
active
07575893
ABSTRACT:
The present invention provides methods for producing humanized antibodies and increasing the yield of antibodies and/or antigen binding fragments when produced in cell culture. In one aspect of the invention, at least one framework region amino acid residue of the variable domain is substituted by a corresponding amino acid from a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequence of the variable domain. In another aspect, an amino acid is placed at a position proximal to a cys residue that participates in an intrachain variable domain disulfide bond that corresponds to an amino acid found at that position in a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequenc of the variable domain.
REFERENCES:
patent: 3645090 (1972-02-01), Mochizuki et al.
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3940475 (1976-02-01), Gross
patent: RE30985 (1982-06-01), Cartaya
patent: 4560655 (1985-12-01), Baker
patent: 4657866 (1987-04-01), Kumar
patent: 4737456 (1988-04-01), Weng et al.
patent: 4767704 (1988-08-01), Cleveland et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4927762 (1990-05-01), Darfler
patent: 4943529 (1990-07-01), Van de Berg et al.
patent: 5122469 (1992-06-01), Mather et al.
patent: 5225539 (1993-07-01), Winter
patent: 5264365 (1993-11-01), Georgiou et al.
patent: 5508192 (1996-04-01), Georgiou et al.
patent: 5534615 (1996-07-01), Baker et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5558564 (1996-09-01), Ascalon
patent: 5589369 (1996-12-01), Seidman et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5639635 (1997-06-01), Joly et al.
patent: 5648237 (1997-07-01), Carter
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5747662 (1998-05-01), Simmons et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840523 (1998-11-01), Simmons et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5869619 (1999-02-01), Studnicka
patent: 6027888 (2000-02-01), Georgiou et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6083715 (2000-07-01), Georgiou et al.
patent: 6172213 (2001-01-01), Lowman et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6455279 (2002-09-01), Ambrosius et al.
patent: 6479284 (2002-11-01), Marasco et al.
patent: 6602688 (2003-08-01), Opper et al.
patent: 6632926 (2003-10-01), Chen et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6767996 (2004-07-01), Gorman et al.
patent: 6800738 (2004-10-01), Carter et al.
patent: 6881557 (2005-04-01), Foote
patent: 6884879 (2005-04-01), Baca et al.
patent: 7098006 (2006-08-01), Gorman et al.
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: 2002/0151682 (2002-10-01), Athwal et al.
patent: 2002/0177170 (2002-11-01), Luo et al.
patent: 0 139 383 (1985-05-01), None
patent: 0 402 226 (1990-12-01), None
patent: 0 183 070 (1991-10-01), None
patent: 0 394 538 (1996-10-01), None
patent: 0 549 581 (1997-01-01), None
patent: 0 244 234 (2001-11-01), None
patent: WO 87/00195 (1987-01-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 90/03430 (1990-04-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/00357 (1991-01-01), None
patent: WO 92/05274 (1992-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO 99/64460 (1999-12-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 00/37502 (2000-06-01), None
patent: WO 01/32712 (2001-05-01), None
patent: WO 01/70984 (2001-09-01), None
patent: WO 01/83806 (2001-11-01), None
patent: WO 02/056910 (2002-07-01), None
patent: WO 02/061090 (2002-08-01), None
patent: WO 03/018771 (2003-03-01), None
patent: WO 03/018771 (2003-03-01), None
patent: WO 2004/006955 (2004-01-01), None
Abaza et al, J of Protein Chemistry 11(5): 433-444, 1992.
Rudikoff e tal, Proc Natl Acad Sci USA 79: 1979, 1983.
Foote et al, J Mol Biol 224: 487-499, 1992.
Kolbinger et al, Protein Engineering 6(8): 971-980, 1993.
Wu et al, J Mol. Biol 294: 151-162, 1999.
Anthony, “Metabolism in the methylotrophic yeasts”,The Biochemistry of Methylotrophs, Chap. 10, pp. 269-292 (1982).
Bachmann, “Derivations and Genotypes of Some Mutant Derivatives ofEscherichia coliK-12”,Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, American Society for Microbiology, 2:1190-1219 (ATCC Deposit No. 27,325) (1987).
Ballance et al., “Transformation ofAspergillus nidulansby the Orotidine-5′-Phosphate Decarboxylase Gene ofNeurospora crassa”, Biochem. Biophys. Res. Commun., 112(1):284-289 (1983).
Barnes et al., “Methods for Growth of Cultured Cells in Serum-Free Medium”,Anal. Biochem., 102:255-270 (1980).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties”,Proteins, 8:309-314 (1990).
Beach et al., “High-frequency transformation of the fission yeastSchizosaccharomyces pombe”, Nature, 290:140-142 (1981).
Case et al., “Efficient Transformation ofNeurospora crassaby Utilizing Hybrid Plasmid DNA”,Proc. Natl. Acad. Sci. USA, 76:5259-5263 (1979).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”,J. Mol. Biol., 293:865-881 (1999).
Co et al., “Humanized antibodies for therapy”,Nature, 351 :501-502 (1991).
David et al., “Protein Iodination with Solid State Lactoperoxidase”,Biochemistry, 13:1014-1021 (1974).
Fleer et al., “Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin byKluyveromycesYeasts”,Bio/Technology, 9:968-975 (1991).
Ham et al., “Media and Growth Requirements”,Meth. Enz., 58:44-93 (1979).
Hara et al., “Overproduction of Penicillin-Binding Protein 7 Suppresses Thermosensitive Growth Defect at Low Osmolarity due to ansprMutation ofEscherichia coli”, Microbiol. Drug Resistance, 2:63-72 (1996).
Harris, “Therapeutic Monoclonals”,Biochem. Soc. Transactions, 23:1035-1038 (1995).
Hunter et al., “Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity”,Nature, 194:495-496 (1962).
Hurle et al., “Protein engineering techniques for antibody humanization”,Curr. Op. Biotech, 5:428-433 (1994).
Jäger et al., “Folding and Assembly of an Antibody Fv Fragment , a Heterodimer Stabilized by Antigen”,J. Mol. Biol., 285:2005-2019 (1999).
Joly et al., “Overexpression ofEscherichia colioxidoreductases increases recombinant insulin-like growth factor-I accumulation”,Proc. Natl. Acad. Sci. USA, 95:2773-2777 (1998).
Kabat et al., “Sequence of Proteins of Immunological Interest”,National Institute of Health(4th Ed.) pp. 41-42, 167-178 (1991).
Kabat et al., “Sequence of Proteins of Immunological Interest”,National Institute of Health, Public Health Service(5th Ed.), pp. 647-669 (1991).
Kelly et al., “Transformation ofAspergillus nigerby theamdSgene ofAspergillus nidulans”, EMBO J., 4:475-479 (1985).
Kikuchi et al., “The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (phoA) ofEscherichia coli”, Nucleic Acids Res., 9(21):5671-5678 (1981).
Knappik et al., “Engineered turns of a recombinant antibody improve its in vivo folding”,Protein Engineering, 8(1):81-89 (1995).
Kostelny et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers”,J. Immunol., 148:1547-1553 (1992).
Li et al., “Influences of amino acid sequences in FRI region on binding activity of the scFv and Fab of an antibody to human gastric cancer cells”,Immunology Letters, 71:157-165 (2000).
Lindmark et al., “Binding of Immunoglobulins to Protein A and Immunoglobulin Levels in Mammalian Seraȁ
Genentech Inc.
Huynh Phuong
Morrison & Foerster / LLP
LandOfFree
Methods for producing humanized antibodies and improving... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for producing humanized antibodies and improving..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for producing humanized antibodies and improving... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4060182